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A detailed kinetic study of the interactions between BRL 42715, a b-lactamase-inhibiting penem, and various
b-lactamases (EC 3.5.2.6) and D-alanyl-D-alanine peptidases (DD-peptidases, EC 3.4.16.4) is presented. The
compound was a very efficient inactivator of all active-site serine b-lactamases but was hydrolyzed by the class
B, Zn21-containing enzymes, with very different kcat values. Inactivation of the Streptomyces sp. strain R61
extracellular DD-peptidase was not observed, and the Actinomadura sp. strain R39 DD-peptidase exhibited a
low level of sensitivity to the compound.
The production of b-lactamases by clinical isolates continues
to be the main mechanism of bacterial resistance to b-lactam
antibiotics. Whilst antibacterial therapy with b-lactamase-sta-
ble compounds has been partially successful in containing the
problem, absolute stability has not been achieved with any one
agent. Clinical experience has established that a second ap-
proach, using a specific b-lactamase inhibitor coadministered
with a b-lactamase-labile antibiotic, offers a viable therapeutic
option for combatting b-lactamase-mediated resistance. Al-
though the three b-lactamase inhibitors in clinical use (clavu-
lanic acid, sulbactam, and tazobactam) are effective inactiva-
tors of a wide range of b-lactamases, they do not inhibit all of
the clinically important enzymes (4, 25).
Of recent interest is the penem b-lactamase inhibitor, BRL
42715 (Fig. 1A), which is synthesized following a stereocon-
trolled reaction sequence starting from the chiral synthon,
6-aminopenicillanic acid (23). BRL 42715 alone possesses no
appreciable antibacterial activity (MIC, 16 to 64 mg/ml) except
against the methicillin-sensitive staphylococci (MIC, 1 mg/ml).
In cell-free b-lactamase assays, this inhibitor shows intrinsic
activity which is superior to that of clavulanic acid, sulbactam,
or tazobactam. Significantly, it is able to inactivate the plasmid-
mediated OXA-1 b-lactamase and the chromosomally medi-
ated enzymes of Enterobacter, Citrobacter, Pseudomonas, Ser-
ratia, andMorganella species, against which the other inhibitors
show poor activity. Its potent inhibitory activity is reflected in
its ability to potentiate the antibacterial properties of a wide
range of b-lactamase-susceptible b-lactam antibiotics, includ-
ing third generation cephalosporins, at very low concentra-
tions. Higher concentrations ('1 mg/ml) are required, how-
ever, against those strains producing elevated levels of class C
b-lactamases (5, 7). The BRL 42715 diffusion rate through the
outer membranes of gram-negative bacteria is similar to those
of sulbactam and tazobactam but lower than that of clavulanic
acid (11). However, thanks to its superior intrinsic activity, it
remains the most active inhibitor against whole cells. In con-
trast to other penems, it is not readily hydrolyzed by the renal
dehydropeptidase (6).
The kinetics of inhibition of b-lactamases of Staphylococcus
aureus NCTC 11561 (class A), Escherichia coli JT4 (TEM-1,
class A), and Enterobacter cloacae P99 (class C) by BRL 42715
has been investigated previously (12). The data show that in-
hibition occurs rapidly and is essentially irreversible and that
the stoichiometry of inhibition is approximately 1:1, indicating
almost zero turnover. With the staphylococcal enzyme, the
enzyme-inhibitor complex decays very slowly, eventually regen-
erating the active enzyme. In the case of TEM-1 and class C
b-lactamases, even after prolonged incubation not all the en-
zyme activity was restored, suggesting the formation of a per-
manently inactivated enzyme-inhibitor complex in addition to
a transiently stable complex (12). A hypothetical pathway for
the interaction mechanism, involving a complex active-site re-
arrangement, has been proposed on the basis of the results
obtained from base- and b-lactamase-catalyzed hydrolysis of
BRL 42715 (3). The major product in these hydrolysis exper-
iments was the dihydrothiazepine rearrangement product (Fig.
1B). Thus, transient or irreversible inhibition of b-lactamases
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FIG. 1. Structure of BRL 42715 [(A) sodium (5R)-(Z)-6-(1-methyl-1,2,3-tria-
zol-4-ylmethylene)penem-3-carboxylate] and of the chromogenic dihydrothiaz-
epine obtained from base- or enzyme-catalyzed hydrolysis of this compound (B).
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by BRL 42715 appears to involve the formation of a cyclic
b-aminoacrylate–enzyme complex.
In this report, we present kinetic data concerning the inter-
actions between BRL 42715 and representative b-lactamases
of classes A, B, C, and D. The Streptomyces sp. strain R61 and
Actinomadura sp. strain R39 D-alanyl-D-alanine peptidases
(DD-peptidases) which have been extensively utilized as model
penicillin-binding proteins were also included in this study to
evaluate the specificity of the inactivating properties of BRL
42715 against active-site serine b-lactamases and DD-pepti-
dases, which constitute two closely related families of penicil-
lin-recognizing enzymes.
MATERIALS AND METHODS
Compounds. BRL 42715 was prepared by Beecham Pharmaceuticals. Nitro-
cefin was purchased from Unipath (Basingstoke, Hants, United Kingdom), and
oxacillin was a kind gift of Bristol Myers-Squibb (Brussels, Belgium). The thio-
lester DD-peptidase substrate C6H5-CO-NH-CH2-CO-S-CH2-COOH was syn-
thesized in Lie`ge, Belgium (1).
Enzymes. The various enzymes studied in the present work are listed in Table
1, which also includes the references in which the purification methods are
described. All enzyme preparations were at least 95% pure.
Kinetic studies. UV and visible spectroscopic recordings were performed with
the help of a Uvikon 860 spectrophotometer linked to a Copam PC microcom-
puter. The hydrolysis of BRL 42715 was directly monitored by recording the A350
variation. Fitting of the data to linear equations was performed with the help of
the Enzfitter program (Elsevier Biosoft, Cambridge, United Kingdom) and of
complete hydrolysis time courses as described before (9). Inactivation experi-
ments were performed by the reporter substrate method (9): pseudo-first-order
inactivation rate constants were measured at increasing inactivator concentra-
tions. The reporter substrate was nitrocefin for all b-lactamases but the OXA-2
enzyme with which oxacillin was used. The different buffers and incubation
temperatures used were as follows: for b-lactamases of classes A, C, and D, 50
mM sodium phosphate, pH 7.0, at 308C; for b-lactamases of class B, 10 mM
sodium cacodylate, pH 7.0, containing 0.1 mM ZnCl2 at 308C for the Aeromonas
hydrophila enzyme or 358C for the other enzymes (a lower temperature was used
for the Aeromonas enzyme because of its significantly poorer heat stability); and
for DD-peptidases, 10 mM sodium phosphate, pH 7.0, at 378C.
Mass spectrometry. BRL 42715 (200 nmol) was incubated for 2 h at 378C with
250 mg of Bacillus cereus 5/B/6 b-lactamase II (class B; Table 2) in 2 ml of 10 mM
sodium cacodylate, pH 6.0, containing 50 mM Zn21. The pH was adjusted to 3.0
with 1 M HCl, and the solution was extracted with ethyl acetate. The organic
phase was dry evaporated, and the solid residue was redissolved in 50 ml of
ethanol. In a similar experiment, 200 nmol of BRL 42715 was incubated for 4 h
at 378C with 1.35 mg of the Streptomyces albus G b-lactamase in 500 ml of 50 mM
sodium phosphate, pH 7.0. The sample was then acidified and extracted. Mass
spectra were obtained with a Quattro VG mass spectrometer equipped with an
electrospray interface (VG Biotech, Manchester, Cheshire, United Kingdom).
Samples (4 ml of ethanol solution) were injected into the electrospray, and the
mass spectra were scanned over the 50- to 600-Da mass range.
RESULTS
Class A b-lactamases: S. albus G and TEM-1. BRL 42715
was hydrolyzed by the S. albus G enzyme, and the time course
of hydrolysis could be followed by UV-visible spectroscopy.
Interestingly, the spectra of the product (P) were the same
when obtained by using sodium hydroxide, the S. albus G, or
one of the Zn21 b-lactamases (see description below) as hy-
drolytic agents. The maximum absorbance variation occurred
at 350 nm (Fig. 2). When monitored at this wavelength and
when the initial BRL 42715 concentration ([C]0) was at least
100 times that of the enzyme ([E]0), a biphasic phenomenon, a
rapid but partial hydrolysis of the b-lactam followed by a much
FIG. 2. Spectral changes recorded during hydrolysis of 500 mM BRL 42715.
(A) hydrolysis by 50 mM sodium hydroxide. The nonhydrolyzed compound
displayed the lowest absorbance values at around 350 nm. Spectra were recorded
at 1-min intervals. The spectrum labelled 1 is that of the intact BRL 42715. (B)
Difference spectra between the hydrolysis product and the intact BRL 42715
(curve 1) (superimposable difference spectra were obtained when the compound
was hydrolyzed by 50 mMNaOH and the S. albusG and Zn21 b-lactamases) and
between the adduct obtained with 70 mM TEM b-lactamase and the starting
compound (curve 2). DA, difference in absorbance spectra.
TABLE 1. Enzymes utilized in this study
Enzyme Class Reference(s)
b-Lactamase from S. albus G A 22
TEM-1 b-lactamase (plasmid pTAC11) A 24, 2




b-Lactamase from A. hydrophilia A2 B 13
b-Lactamase from E. cloacae 908R C 22
OXA-2 b-lactamase (plasmid pDML303) D 21
DD-peptidase from Streptomyces sp.
strain R61
DD-peptidase 14
DD-peptidase from Actinomadura sp.
strain R39
DD-peptidase 18










A. hydrophila 0.22 40 6 5 5.5 z 103
P. maltophilia 511 0.55 270 6 10 2.0 z 103
B. cereus II 121 6 6 1 2.0 z 107
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slower turn-over, was observed. This pattern suggested a
branched pathway, as in the model below:
k11 k2 k3
E 1 C º EC 3 EC* 3 E 1 P
k21 k14 . k24
ECi 3 E 1 P9
k5
An approximate value of the k3/k14 ratio was obtained by
measuring the residual activity after partial (and transient)
inactivation at low [C]0/[E]0 ratios (16). The poor accuracy of
the value obtained (40 6 10) is due to the fact that the inac-
tivated complex (ECi) is not completely stable. This value was
not significantly altered by the presence of high salt concen-
trations (0.5 M NaCl), in contrast with the results obtained
with the same enzyme and b-halogenopenicillanates (10). The
model admits two-limit cases, i.e., k24 5 0 or k5 5 0. The data
presented here do not allow a choice between the various
possibilities (general model or one of the limit cases). For
simplicity’s sake, the situation will be further discussed by as-
suming that k24 5 0, but it should not be considered that this
limit case is more likely than either the other one or the
general model.
The reporter substrate method (with 100 mM nitrocefin) was
used to follow the enzyme inactivation at high [C]0/[E]0 ratios.
The dependency of the inactivation rate on the BRL 42715
concentration is shown by Fig. 3. On the basis of the above
model (where k24 5 0): ki 5 k5 1 A z [C]/(B 1 [C]), where A
5 k2 z k4/(k2 1 k3 1 k4) and B 5 (k3 1 k4) z K9/(k2 1 k3 1 k4),
with K9 5 (k21 1 k2)/k11.
Our data thus allowed the computation of k5 5 2.2 z 10
23
s21 (extrapolation of the line to [C] 5 0) and of A /B 5
k2 z k4/(k3 1 k4) z K9 5 17,000 M
21 s21. On the basis of the
k3/k4 ratio determined above, it can be seen that k2/K9 5
680,0006 170,000 M21 s21. From the same data, the Km value
for the hydrolysis of BRL 42715 after establishment of the final
steady state was determined. A value of 26 nM, corresponding
to Km 5 k5 z (k3 1 k4) z K9 / [k2k5 1 k2k4 1 k5 z (k3 1 k4)] in
model 1, was found.
With the TEM-1 enzyme, the situation was much more sim-
ple. Complete inactivation occurred at a 1/1 molar ratio. With
50 mM nitrocefin as a reporter substrate, the pseudo-first-order
rate constant for inactivation remained proportional to BRL
42715 concentrations up to 20 nM (Fig. 4). From these data,
and taking account of the protection by the reporter substrate,
a k2/K9 value of (2.5 6 0.3) z 10
6 M21 s21 was calculated.
Figure 2B shows the difference in the spectra of the adduct and
the starting compound, indicating clear similarities between
the spectrum of the adduct and that of the hydrolyzed com-
pound (Fig. 2A).
No lag was observed in the increase of A350, which, on the
basis of our model, reflected a very rapid rearrangement of the
initially formed acyl enzyme (EC*) to the stable species (ECi).
The model thus became rather simple, with k24 and k5 close to
zero and k14 much larger than both k2 and k3.
Class C b-lactamase: E. cloacae 908R. No hydrolysis was
observed for the E. cloacae 908R enzyme, but the enzyme was
rapidly inactivated, thus indicating a situation similar to that
observed with the TEM-1 enzyme.
The rate of inactivation at various [C] values was measured
with nitrocefin as a reporter substrate. A linear increase of ki
was found up to [C] 5 100 nM (ki 5 0.12 s
21), from which the
following values were deduced: k2/K9 5 1.2 z 10
6 M21 s21;
with k2 . 0.5 s
21 and k3 , 10
23 s21.
Class D b-lactamase: OXA-2. Again, with OXA-2 no hydro-
lysis of the compound was observed, but rapid, total and irre-
versible inactivation was observed at [C]0/[E]0 values ranging
from 15,000 to 1. With 1 mM oxacillin as a reporter substrate,
the rate of inactivation was found to be independent of the
inactivator concentration above 40 nM [ki5 (2.16 0.2) z 10
22
s21]. On the basis of our model, this would yield k2 5 (2.1 6
0.2) z 1022 s21, k4@k2, k2/K9 .0.5 z 10
6 M21s21, and both k3
and k5 , 10
23 s21.
Class B: Zn21 b-lactamases. In all cases, with Zn21 b-lac-
tamases BRL 42715 behaved as a substrate. The kinetic pa-
rameters are given in Table 2. They were derived from initial
rate measurements and Hanes plots for the A. hydrophila en-
zyme and from complete time courses for the other two en-
zymes.
DD-peptidases. The Actinomadura sp. strain R39 enzyme
was inactivated by BRL 42715. The inactivation was studied
with the thiolester (100 mM) as a reporter substrate in the
presence of 10 mM D-histidine to obtain a first-order hydrolysis
of the thiolester (19). A k2/K9 value of 1,100 6 30 M
21 s21 was
found (with K9 . 40 mM). Conversely, the Streptomyces sp.
strain R61 enzyme (1 mM) was not inactivated after over 5 min
at a BRL 42715 concentration of 100 mM, indicating a k2/K9
value lower than 2 M21 s21.
Identification of the reaction product. The mass spectra of
the compound obtained after extraction of the acidified reac-
tion mixtures exhibited clear peaks at an m/e of 279, for both
FIG. 3. Interaction between the S. albus G b-lactamase and BRL 42715.
Variation of ki with [C] from which an A/B value of 17,000 M21 s21 was obtained
(see Results).
FIG. 4. Interaction between the TEM-1 b-lactamase and BRL 42715. The
variation of ki at low [C] values from which a k2/K9 value of 2.5 z 106 M21 s21
was deduced 6 standard deviations is plotted.
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the B. cereus Zn21 enzyme b-lactamase and the S. albus G
b-lactamase. This corresponds to a molecular ion for dihy-
drothiazepine after the loss of one H. To show that the rear-
rangement was not an artifact due to the extraction procedure,
an aliquot of the ethanol solution was dry evaporated and the
residue was redissolved in 50 mM sodium phosphate, pH 7.0.
The UV spectrum was superimposable on that of the product
of the base- or enzyme-catalyzed hydrolysis (Fig. 2A), indicat-
ing that no further structure modification had occurred.
DISCUSSION
Like several other b-lactams which inactivate active-site
serine b-lactamases, BRL 42715 was hydrolyzed by the Zn21-
containing class B enzymes (13). Hydrolysis was particularly
efficient with the B. cereus enzyme which, fortunately, does not
represent a clinical problem. However, the fact that the three
class B enzymes studied did hydrolyze the compound suggests
that it might be a substrate for most metallo-b-lactamases and
underlines the difficulties which might arise if these enzymes
spread to a large number of pathogenic strains. In agreement
with the results of Broom et al. (3), the spectral properties of
the product were identical to those of the dihydrothiazepine
(Fig. 1B) obtained after sodium hydroxide hydrolysis. The sim-
plest explanation is that a rearrangement of the primary hy-
drolysis product, formed according to the usual (but still mys-
terious) catalytic pathway, takes place after its release from the
enzyme. The mass spectrometry data also confirmed that the
same dihydrothiazepine was obtained after hydrolysis by both
the Zn21 enzyme and the active-site serine S. albus G b-lac-
tamases. As expected from its poor intrinsic antibacterial ac-
tivity, BRL 42715 did not significantly react with the Strepto-
myces sp. strain R61 DD-peptidase and was a rather poor
inactivator of the Actinomadura sp. strain R39 enzyme, which
is generally very sensitive to most b-lactams. These properties
were reminiscent of those of b-iodopenicillanate, which was
also much more active against the latter DD-peptidase (17).
The results obtained with the two model DD-peptidases were
thus consistent with the rather poor intrinsic antibacterial ac-
tivity exhibited by BRL 42715. By contrast, BRL 42715 was an
extremely efficient inactivator of all tested active-site serine
b-lactamases. Table 3 summarizes our results and those ob-
tained earlier (3, 12), with which they were in excellent agree-
ment. On the basis of the model (with k24 ' 0), these enzymes
can be divided into two groups. Enzymes in the first group (S.
albus G and Klebsiella pneumoniae) exhibited a branched path-
way (k3 . k14) and a nonnegligible hydrolysis of the chro-
mophoric ECi adduct (k5Þ 0). All the other enzymes belonged
to the second group, in which the reaction pathway appears to
be linear, with a value of k3 , k14 and a very low k5 value (1.5
z 1024 s21 or less). The spectral properties of the adduct
formed with the TEM-1 enzyme also agreed with the forma-
tion of a seven-membered dihydrothiazepine chromophore.
FIG. 5. General model for the interaction between BRL 42715 and the active-site serine b-lactamases (E-OH). The putative stable intermediates of the model
presented in Results (EC* and ECi) are tentatively identified. Broken lines represent the reaction steps actually detected by the kinetic and spectroscopic methods.
TABLE 3. Acylation rate constants of various active-site serine enzymes by BRL 42715
Source of enzyme Enzyme typeand class k2/K9 (mM
21 s21) k3/k4 (C0/E0)ia k5(s21)
TEM-1 b-Lactamase, A 2.5, 6.4b 0 1 1.6 z 1024b
S. aureus NCTC 11561 b-Lactamase, A 0.17b 0b 1 3.6 z 1026b
S. albus G b-Lactamase, A 0.68 40 6 10 40 6 10 2.2 z 1023
K. pneumoniae K1 b-Lactamase, A NDc .1 .2 6 z 1022d
E. cloacae P99 b-Lactamase, C 1.2, 2.5b 0 1 1.2 z 1025b
OXA-2 b-Lactamase, D .0.5 0 1 ND
Streptomyces sp. strain R61 DD-peptidase —e — — —
Actinomadura sp. strain R39 DD-peptidase 1.1 z 1023 0 1 ND
a (C0/E0)i, C0/E0 values leading to complete inactivation.
b Data from reference 12.
c ND, not determined.
d Data from reference 3.
e—, no interaction (k2/K , 2 M21 s21).
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The data presently available indicate that branched pathways
occur only with class A enzymes, but it should be stressed that
only one representative each of class C and D has been stud-
ied. Figure 5 diagrams a proposed general interaction model
based on the previously obtained chemical evidence and on our
mass spectrometry results, where the initially formed acyl-en-
zyme (EC*) can undergo both hydrolysis and rapid rearrange-
ment to the more stable dihydrothiazepine-containing adduct.
If this model is correct, the assumption that k24 is '0 is
probably justified. The hydrolysis product observed when k3 is
larger than k4 also rapidly rearranges into the chromophoric
dihydrothiazepine. All these results are very similar to those
observed in the interactions between various b-lactamases and
b-halogenopenicillanates (9, 15). In contrast to the situation
prevailing with these compounds, the presence of high salt
concentrations did not modify the k3/k4 ratio, indicating that
this ‘‘salt effect’’ was a specific property of the rearrangement
reaction of the acyl-enzyme formed with b-halogenopenicilla-
nates (10). Finally, it was also noted earlier that the slow
reactivation observed with the TEM and P99 (which is nearly
identical to 908R) b-lactamases was not complete, suggesting
the formation of an additional species even more stable than
ECi. The P99 adduct could arise from either EC*, as hypoth-
esized for the interaction between the TEM enzyme and cla-
vulanic acid (20), or ECi. Since the dihydrothiazepine moiety
of the ECi adduct appears to be rather stable, further modifi-
cation of ECimight involve an alteration of the enzyme tertiary
structure.
The results presented here demonstrate that BRL 42715 is
an extremely efficient inactivator of all active-site serine b-lac-
tamases, a very unique, specific, and interesting property. In-
deed, most other mechanism-based inactivators of active-site
serine b-lactamases (e.g., clavulanic acid and sulbactam) gen-
erally exhibit rather poor activity against class C enzymes. BRL
42715 is however hydrolyzed by all the class B enzymes studied.
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ADDENDUM IN PROOF
While this paper was in press, Farmer et al. (Biochem. J.
303:825–830, 1994) published results obtained with the same
compound which were in excellent agreement with the present
data.
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